These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Improving Preclinical Development of Novel Interventions to Treat Pain: Insanity Is Doing the Same Thing Over and Over and Expecting Different Results. Eisenach JC; Rice ASC Anesth Analg; 2022 Dec; 135(6):1128-1136. PubMed ID: 36384008 [TBL] [Abstract][Full Text] [Related]
3. Shedding light on neuropathic pain: Current and emerging tools for diagnosis, screening, and quantification. Hamdan A; Galvez R; Katati M SAGE Open Med; 2024; 12():20503121231218985. PubMed ID: 38343869 [TBL] [Abstract][Full Text] [Related]
5. John D. Loeser Award Lecture: Size does matter, but it isn't everything: the challenge of modest treatment effects in chronic pain clinical trials. Smith SM; Fava M; Jensen MP; Mbowe OB; McDermott MP; Turk DC; Dworkin RH Pain; 2020 Sep; 161 Suppl 1(1):S3-S13. PubMed ID: 33090735 [No Abstract] [Full Text] [Related]
6. Research designs for proof-of-concept chronic pain clinical trials: IMMPACT recommendations. Gewandter JS; Dworkin RH; Turk DC; McDermott MP; Baron R; Gastonguay MR; Gilron I; Katz NP; Mehta C; Raja SN; Senn S; Taylor C; Cowan P; Desjardins P; Dimitrova R; Dionne R; Farrar JT; Hewitt DJ; Iyengar S; Jay GW; Kalso E; Kerns RD; Leff R; Leong M; Petersen KL; Ravina BM; Rauschkolb C; Rice ASC; Rowbotham MC; Sampaio C; Sindrup SH; Stauffer JW; Steigerwald I; Stewart J; Tobias J; Treede RD; Wallace M; White RE Pain; 2014 Sep; 155(9):1683-1695. PubMed ID: 24865794 [TBL] [Abstract][Full Text] [Related]
7. Regulatory perspectives on multiplicity in adaptive design clinical trials throughout a drug development program. Wang SJ; Hung HM; O'Neill R J Biopharm Stat; 2011 Jul; 21(4):846-59. PubMed ID: 21516573 [TBL] [Abstract][Full Text] [Related]
8. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626 [TBL] [Abstract][Full Text] [Related]
9. A Bayesian adaptive design for multi-dose, randomized, placebo-controlled phase I/II trials. Xie F; Ji Y; Tremmel L Contemp Clin Trials; 2012 Jul; 33(4):739-48. PubMed ID: 22426247 [TBL] [Abstract][Full Text] [Related]
10. Accelerating the development of improved analgesic treatments: the ACTION public-private partnership. Dworkin RH; Turk DC Pain Med; 2011 Jul; 12 Suppl 3():S109-17. PubMed ID: 21752182 [TBL] [Abstract][Full Text] [Related]
11. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints. Jenkins M; Stone A; Jennison C Pharm Stat; 2011; 10(4):347-56. PubMed ID: 22328327 [TBL] [Abstract][Full Text] [Related]
12. Early phase drug development for treatment of chronic pain--options for clinical trial and program design. Kalliomäki J; Miller F; Kågedal M; Karlsten R Contemp Clin Trials; 2012 Jul; 33(4):689-99. PubMed ID: 22401888 [TBL] [Abstract][Full Text] [Related]